uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.1006 | Q16 | What Small molecule therapies have been approved by the FDA to treat drug-Induced dyskinesia? | There are no drug Small molecule therapies approved to treat drug-Induced dyskinesia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "drug-induced dyskinesia" OR LOWER(mesh_heading) = "drug-induced dyskinesia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.824 | Q16 | What Small molecule therapies have been approved by the FDA to treat bipolar I disorder? | There are 10 Small molecule therapy drugs that are approved to treat bipolar I disorder which are as follows: Loxapine, Risperidone, Aripiprazole Lauroxil, Aripiprazole, Asenapine Maleate, Asenapine, Lurasidone Hydrochloride, Cariprazine Hydrochloride, Carbamazepine, and Lamotrigine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bipolar i disorder" OR LOWER(mesh_heading) = "bipolar i disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149053', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149065', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149077', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149089', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149101', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149113', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149125', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149137', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149149', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149161', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149173', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149185', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149197', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149209', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149221', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149233', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149245', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149257', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149269', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149281', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149293', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149305', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149317', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149329', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149341', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149353', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149365', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149377', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149389', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149401', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149413', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149425', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149437', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149449', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149461', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149492', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149525', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149558', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149591', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149624', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149657', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149690', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149723', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149756', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149789', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149822', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149855', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149888', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149921', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149954', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149987', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150020', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150053', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150086', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150119', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150152', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150185', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150218', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150251', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150284', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150317', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150350', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150383', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150416', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150449', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150482', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150515', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150548', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150581', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150614', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150647', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150680', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150713', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150746', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150779', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150812', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150845', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150878', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150911', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150944', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150977', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151010', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151043', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151076', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151109', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151142', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151175', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151208', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151241', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_157999', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158005', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158011', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158017', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158023', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158029', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158035', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158041', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158047', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158053', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}, {'UUID': 'DrugTargetsIndication121923_text_158059', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.790 | Q16 | What Small molecule therapies have been approved by the FDA to treat aspergillosis? | There are no drug Small molecule therapies approved to treat aspergillosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aspergillosis" OR LOWER(mesh_heading) = "aspergillosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.482 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hepatitis, Alcoholic? | There are no drug Small molecule therapies approved to treat Hepatitis, Alcoholic. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatitis, alcoholic" OR LOWER(mesh_heading) = "hepatitis, alcoholic") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.200 | Q16 | What Protein therapies have been approved by the FDA to treat leukemia? | There are no drug Protein therapies approved to treat leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "leukemia" OR LOWER(mesh_heading) = "leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.951 | Q16 | What Small molecule therapies have been approved by the FDA to treat conduct disorder? | There are no drug Small molecule therapies approved to treat conduct disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "conduct disorder" OR LOWER(mesh_heading) = "conduct disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.468 | Q16 | What Small molecule therapies have been approved by the FDA to treat HIV-1 infection? | There are 2 Small molecule therapy drugs that are approved to treat HIV-1 infection which are as follows: Maraviroc and Cobicistat. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hiv-1 infection" OR LOWER(mesh_heading) = "hiv-1 infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938284', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938305', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938326', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938347', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938368', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938389', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938410', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938431', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938452', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938473', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938494', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938515', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938536', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938557', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_938578', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148776', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148787', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148798', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148809', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148820', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148831', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148842', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148853', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148864', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148875', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148886', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148897', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148908', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148919', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148930', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148941', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.497 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hypercalcemia? | There are 2 Small molecule therapy drugs that are approved to treat Hypercalcemia which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypercalcemia" OR LOWER(mesh_heading) = "hypercalcemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217625', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_217833', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_218041', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_218249', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_218457', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_218665', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_218873', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_219081', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_219289', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_219497', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_219705', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_219913', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_220121', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_220329', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_220537', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_220745', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_226316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_226601', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_226886', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_227171', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_227456', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_227741', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_228026', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_228311', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_228596', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_228881', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_229166', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_229451', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_229736', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_230021', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_230306', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_230591', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_230876', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_231161', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_231446', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_231731', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_232016', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}, {'UUID': 'DrugTargetsIndication121923_text_232301', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.419 | Q16 | What Small molecule therapies have been approved by the FDA to treat Dyspareunia? | There are 2 Small molecule therapy drugs that are approved to treat Dyspareunia which are as follows: Ospemifene and Estradiol. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dyspareunia" OR LOWER(mesh_heading) = "dyspareunia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823726', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823730', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823734', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823738', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823742', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823746', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823750', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823754', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823758', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823762', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823766', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823770', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823774', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823778', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823782', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823786', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823790', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823794', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823798', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823802', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823806', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823810', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823814', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823818', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823822', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823826', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823830', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823834', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823838', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823842', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823846', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823850', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823854', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823858', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823862', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823866', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823870', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823874', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_823979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_824979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_825979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}, {'UUID': 'DrugTargetsIndication121923_text_826979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.538 | Q16 | What Small molecule therapies have been approved by the FDA to treat MALT lymphoma? | There are no drug Small molecule therapies approved to treat MALT lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malt lymphoma" OR LOWER(mesh_heading) = "malt lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1147 | Q16 | What Small molecule therapies have been approved by the FDA to treat hereditary hemorrhagic telangiectasia? | There are no drug Small molecule therapies approved to treat hereditary hemorrhagic telangiectasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hereditary hemorrhagic telangiectasia" OR LOWER(mesh_heading) = "hereditary hemorrhagic telangiectasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1544 | Q16 | What Small molecule therapies have been approved by the FDA to treat psychosis? | There are 10 Small molecule therapy drugs that are approved to treat psychosis which are as follows: Loxapine, Risperidone, Amisulpride, Brexpiprazole, Clozapine, Aripiprazole, Asenapine, Lurasidone, Iloperidone, and Pimavanserin Tartrate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "psychosis" OR LOWER(mesh_heading) = "psychosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149052', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149064', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149076', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149088', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149100', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149112', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149124', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149136', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149148', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149160', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149172', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149184', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149196', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149208', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149220', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149232', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149244', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149256', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149268', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149280', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149292', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149304', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149316', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149328', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149340', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149352', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149364', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149376', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000069696', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149388', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149400', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149412', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149424', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149436', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149448', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149460', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149490', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149523', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149556', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149589', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149622', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149655', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149688', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149721', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149754', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149787', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149820', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149853', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149886', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149919', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149952', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_149985', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150018', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150051', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150084', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150117', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150150', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150183', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150216', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150249', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150282', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150315', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150348', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150381', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150414', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150447', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150480', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150513', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150546', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150579', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150612', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150645', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150678', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150711', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150744', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150777', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150810', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150843', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150876', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150909', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150942', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_150975', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151008', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151041', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151074', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151107', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151140', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151173', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151206', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151239', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151448', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151461', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151474', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151487', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151500', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151513', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151526', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151539', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151552', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151565', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}, {'UUID': 'DrugTargetsIndication121923_text_151578', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1114 | Q16 | What Small molecule therapies have been approved by the FDA to treat gonorrhea? | Doxycycline is the only Small molecule therapy approved by the FDA to treat gonorrhea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gonorrhea" OR LOWER(mesh_heading) = "gonorrhea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1037840', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1037915', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1037990', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038065', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038140', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038215', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038290', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038365', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038440', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038515', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038590', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038665', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038740', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038815', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038890', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1038965', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039040', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039115', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039190', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039265', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039340', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039415', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039490', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039565', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039640', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039715', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039790', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039865', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1039940', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040015', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040090', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040165', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040240', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040315', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040390', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040465', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040540', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040615', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040690', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040765', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040840', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040915', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1040990', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_1041065', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gonorrhea', 'efo_term': 'gonorrhea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1190 | Q16 | What Small molecule therapies have been approved by the FDA to treat inclusion body myositis? | There are no drug Small molecule therapies approved to treat inclusion body myositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "inclusion body myositis" OR LOWER(mesh_heading) = "inclusion body myositis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.840 | Q16 | What Small molecule therapies have been approved by the FDA to treat brain infarction? | There are no drug Small molecule therapies approved to treat brain infarction. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain infarction" OR LOWER(mesh_heading) = "brain infarction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.897 | Q16 | What Small molecule therapies have been approved by the FDA to treat childhood ependymoma? | There are no drug Small molecule therapies approved to treat childhood ependymoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "childhood ependymoma" OR LOWER(mesh_heading) = "childhood ependymoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.312 | Q16 | What Protein therapies have been approved by the FDA to treat type 2 diabetes mellitus? | There are 4 Protein therapy drugs that are approved to treat type 2 diabetes mellitus which are as follows: Liraglutide, Tirzepatide, Exenatide, and Semaglutide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "type 2 diabetes mellitus" OR LOWER(mesh_heading) = "type 2 diabetes mellitus") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044425', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044448', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044471', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044494', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044517', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044540', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044563', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044586', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044609', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044632', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044655', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044678', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044701', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044724', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044747', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044770', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044793', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044816', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044839', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044862', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044885', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044908', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044931', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044954', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044977', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045000', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045023', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045046', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045069', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045092', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045115', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045138', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045161', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045184', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045207', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045230', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045253', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045276', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045299', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045322', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045345', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045368', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045391', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045414', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045437', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045460', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045483', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045506', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045529', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045552', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045575', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045598', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045621', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045644', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045667', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045690', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045713', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045716', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045719', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045722', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045725', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045728', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045731', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045734', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045737', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045740', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045743', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045746', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045749', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045752', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045755', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045758', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045761', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045764', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045767', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045770', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045773', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045776', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045779', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045782', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045785', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000112164', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045788', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045791', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045794', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045797', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045800', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045803', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045806', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045809', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045812', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045815', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045818', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045821', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045824', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045827', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045830', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045833', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045836', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045839', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1045842', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000010310', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.57 | Q16 | What Protein therapies have been approved by the FDA to treat Prader-Willi syndrome? | There are no drug Protein therapies approved to treat Prader-Willi syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prader-willi syndrome" OR LOWER(mesh_heading) = "prader-willi syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1644 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinal cord neoplasm? | There are no drug Small molecule therapies approved to treat spinal cord neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal cord neoplasm" OR LOWER(mesh_heading) = "spinal cord neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.386 | Q16 | What Small molecule therapies have been approved by the FDA to treat Chlamydia trachomatis infectious disease? | There are no drug Small molecule therapies approved to treat Chlamydia trachomatis infectious disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chlamydia trachomatis infectious disease" OR LOWER(mesh_heading) = "chlamydia trachomatis infectious disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1169 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypogonadotropic hypogonadism? | There are 2 Small molecule therapy drugs that are approved to treat hypogonadotropic hypogonadism which are as follows: Testosterone Undecanoate and Testosterone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypogonadotropic hypogonadism" OR LOWER(mesh_heading) = "hypogonadotropic hypogonadism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921815', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921824', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921833', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921842', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921976', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921989', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922002', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922015', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922028', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922041', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922054', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922067', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922080', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922093', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922106', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922119', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922132', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922145', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922158', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922171', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922184', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922197', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922210', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922223', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922236', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922249', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922262', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922275', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922288', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922301', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922314', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922327', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922340', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922353', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922366', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922379', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922392', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922405', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922418', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922431', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922444', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922457', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922470', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922483', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922496', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922524', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922528', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922560', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922564', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922596', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.44 | Q16 | What Protein therapies have been approved by the FDA to treat Hodgkins lymphoma? | There are no drug Protein therapies approved to treat Hodgkins lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hodgkins lymphoma" OR LOWER(mesh_heading) = "hodgkins lymphoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.101 | Q16 | What Protein therapies have been approved by the FDA to treat autoimmune thrombocytopenic purpura? | There are no drug Protein therapies approved to treat autoimmune thrombocytopenic purpura. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autoimmune thrombocytopenic purpura" OR LOWER(mesh_heading) = "autoimmune thrombocytopenic purpura") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.276 | Q16 | What Protein therapies have been approved by the FDA to treat prostate neoplasm? | There are no drug Protein therapies approved to treat prostate neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate neoplasm" OR LOWER(mesh_heading) = "prostate neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1432 | Q16 | What Small molecule therapies have been approved by the FDA to treat ovarian serous cystadenocarcinoma? | There are no drug Small molecule therapies approved to treat ovarian serous cystadenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ovarian serous cystadenocarcinoma" OR LOWER(mesh_heading) = "ovarian serous cystadenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.356 | Q16 | What Small molecule therapies have been approved by the FDA to treat B-cell neoplasm? | There are no drug Small molecule therapies approved to treat B-cell neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "b-cell neoplasm" OR LOWER(mesh_heading) = "b-cell neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.102 | Q16 | What Protein therapies have been approved by the FDA to treat benign muscle neoplasm? | There are no drug Protein therapies approved to treat benign muscle neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "benign muscle neoplasm" OR LOWER(mesh_heading) = "benign muscle neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1134 | Q16 | What Small molecule therapies have been approved by the FDA to treat hematopoietic and lymphoid system neoplasm? | There are no drug Small molecule therapies approved to treat hematopoietic and lymphoid system neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hematopoietic and lymphoid system neoplasm" OR LOWER(mesh_heading) = "hematopoietic and lymphoid system neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.108 | Q16 | What Protein therapies have been approved by the FDA to treat brain neoplasm? | There are no drug Protein therapies approved to treat brain neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain neoplasm" OR LOWER(mesh_heading) = "brain neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1219 | Q16 | What Small molecule therapies have been approved by the FDA to treat invasive lobular carcinoma? | There are no drug Small molecule therapies approved to treat invasive lobular carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "invasive lobular carcinoma" OR LOWER(mesh_heading) = "invasive lobular carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1744 | Q16 | What Small molecule therapies have been approved by the FDA to treat vascular disease? | There are no drug Small molecule therapies approved to treat vascular disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vascular disease" OR LOWER(mesh_heading) = "vascular disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.730 | Q16 | What Small molecule therapies have been approved by the FDA to treat alcohol dependence? | There are 2 Small molecule therapy drugs that are approved to treat alcohol dependence which are as follows: Doxepin Hydrochloride and Naltrexone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alcohol dependence" OR LOWER(mesh_heading) = "alcohol dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440778', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440786', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440794', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440802', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440810', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440818', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440826', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440834', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440842', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440850', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440858', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440866', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440874', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440882', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440890', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440898', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440906', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440914', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440922', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440930', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440938', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440946', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440954', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440962', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440970', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440978', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440986', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_440994', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_441002', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_441010', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_785065', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_785110', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_785155', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_785200', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_785245', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}, {'UUID': 'DrugTargetsIndication121923_text_785290', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1271 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphoid leukemia? | There are no drug Small molecule therapies approved to treat lymphoid leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoid leukemia" OR LOWER(mesh_heading) = "lymphoid leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.597 | Q16 | What Small molecule therapies have been approved by the FDA to treat Postpericardiotomy Syndrome? | There are no drug Small molecule therapies approved to treat Postpericardiotomy Syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "postpericardiotomy syndrome" OR LOWER(mesh_heading) = "postpericardiotomy syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.555 | Q16 | What Small molecule therapies have been approved by the FDA to treat Myasthenia gravis? | There are no drug Small molecule therapies approved to treat Myasthenia gravis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myasthenia gravis" OR LOWER(mesh_heading) = "myasthenia gravis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_968358', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000053918', 'approvedSymbol': 'KCNQ1', 'approvedName': 'potassium voltage-gated channel subfamily Q member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968363', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000053918', 'approvedSymbol': 'KCNQ1', 'approvedName': 'potassium voltage-gated channel subfamily Q member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968368', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000053918', 'approvedSymbol': 'KCNQ1', 'approvedName': 'potassium voltage-gated channel subfamily Q member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968373', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000053918', 'approvedSymbol': 'KCNQ1', 'approvedName': 'potassium voltage-gated channel subfamily Q member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968378', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000053918', 'approvedSymbol': 'KCNQ1', 'approvedName': 'potassium voltage-gated channel subfamily Q member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968383', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000053918', 'approvedSymbol': 'KCNQ1', 'approvedName': 'potassium voltage-gated channel subfamily Q member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968388', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000171385', 'approvedSymbol': 'KCND3', 'approvedName': 'potassium voltage-gated channel subfamily D member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968393', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000171385', 'approvedSymbol': 'KCND3', 'approvedName': 'potassium voltage-gated channel subfamily D member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968398', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000171385', 'approvedSymbol': 'KCND3', 'approvedName': 'potassium voltage-gated channel subfamily D member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968403', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000171385', 'approvedSymbol': 'KCND3', 'approvedName': 'potassium voltage-gated channel subfamily D member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968408', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000171385', 'approvedSymbol': 'KCND3', 'approvedName': 'potassium voltage-gated channel subfamily D member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968413', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000171385', 'approvedSymbol': 'KCND3', 'approvedName': 'potassium voltage-gated channel subfamily D member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968418', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968423', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968428', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968433', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968438', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968443', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968448', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177301', 'approvedSymbol': 'KCNA2', 'approvedName': 'potassium voltage-gated channel subfamily A member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968453', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177301', 'approvedSymbol': 'KCNA2', 'approvedName': 'potassium voltage-gated channel subfamily A member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968458', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177301', 'approvedSymbol': 'KCNA2', 'approvedName': 'potassium voltage-gated channel subfamily A member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968463', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177301', 'approvedSymbol': 'KCNA2', 'approvedName': 'potassium voltage-gated channel subfamily A member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968468', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177301', 'approvedSymbol': 'KCNA2', 'approvedName': 'potassium voltage-gated channel subfamily A member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968473', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177301', 'approvedSymbol': 'KCNA2', 'approvedName': 'potassium voltage-gated channel subfamily A member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968478', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000111262', 'approvedSymbol': 'KCNA1', 'approvedName': 'potassium voltage-gated channel subfamily A member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968483', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000111262', 'approvedSymbol': 'KCNA1', 'approvedName': 'potassium voltage-gated channel subfamily A member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968488', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000111262', 'approvedSymbol': 'KCNA1', 'approvedName': 'potassium voltage-gated channel subfamily A member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968493', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000111262', 'approvedSymbol': 'KCNA1', 'approvedName': 'potassium voltage-gated channel subfamily A member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968498', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000111262', 'approvedSymbol': 'KCNA1', 'approvedName': 'potassium voltage-gated channel subfamily A member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968503', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000111262', 'approvedSymbol': 'KCNA1', 'approvedName': 'potassium voltage-gated channel subfamily A member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968508', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000075043', 'approvedSymbol': 'KCNQ2', 'approvedName': 'potassium voltage-gated channel subfamily Q member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968513', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000075043', 'approvedSymbol': 'KCNQ2', 'approvedName': 'potassium voltage-gated channel subfamily Q member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968518', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000075043', 'approvedSymbol': 'KCNQ2', 'approvedName': 'potassium voltage-gated channel subfamily Q member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968523', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000075043', 'approvedSymbol': 'KCNQ2', 'approvedName': 'potassium voltage-gated channel subfamily Q member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968528', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000075043', 'approvedSymbol': 'KCNQ2', 'approvedName': 'potassium voltage-gated channel subfamily Q member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968533', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000075043', 'approvedSymbol': 'KCNQ2', 'approvedName': 'potassium voltage-gated channel subfamily Q member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968538', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184156', 'approvedSymbol': 'KCNQ3', 'approvedName': 'potassium voltage-gated channel subfamily Q member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968543', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184156', 'approvedSymbol': 'KCNQ3', 'approvedName': 'potassium voltage-gated channel subfamily Q member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968548', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184156', 'approvedSymbol': 'KCNQ3', 'approvedName': 'potassium voltage-gated channel subfamily Q member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968553', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184156', 'approvedSymbol': 'KCNQ3', 'approvedName': 'potassium voltage-gated channel subfamily Q member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968558', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184156', 'approvedSymbol': 'KCNQ3', 'approvedName': 'potassium voltage-gated channel subfamily Q member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968563', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184156', 'approvedSymbol': 'KCNQ3', 'approvedName': 'potassium voltage-gated channel subfamily Q member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968568', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000104848', 'approvedSymbol': 'KCNA7', 'approvedName': 'potassium voltage-gated channel subfamily A member 7', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968573', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000104848', 'approvedSymbol': 'KCNA7', 'approvedName': 'potassium voltage-gated channel subfamily A member 7', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968578', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000104848', 'approvedSymbol': 'KCNA7', 'approvedName': 'potassium voltage-gated channel subfamily A member 7', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968583', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000104848', 'approvedSymbol': 'KCNA7', 'approvedName': 'potassium voltage-gated channel subfamily A member 7', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968588', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000104848', 'approvedSymbol': 'KCNA7', 'approvedName': 'potassium voltage-gated channel subfamily A member 7', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968593', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000104848', 'approvedSymbol': 'KCNA7', 'approvedName': 'potassium voltage-gated channel subfamily A member 7', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968598', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185760', 'approvedSymbol': 'KCNQ5', 'approvedName': 'potassium voltage-gated channel subfamily Q member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968603', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185760', 'approvedSymbol': 'KCNQ5', 'approvedName': 'potassium voltage-gated channel subfamily Q member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968608', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185760', 'approvedSymbol': 'KCNQ5', 'approvedName': 'potassium voltage-gated channel subfamily Q member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968613', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185760', 'approvedSymbol': 'KCNQ5', 'approvedName': 'potassium voltage-gated channel subfamily Q member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968618', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185760', 'approvedSymbol': 'KCNQ5', 'approvedName': 'potassium voltage-gated channel subfamily Q member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968623', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185760', 'approvedSymbol': 'KCNQ5', 'approvedName': 'potassium voltage-gated channel subfamily Q member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968628', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000117013', 'approvedSymbol': 'KCNQ4', 'approvedName': 'potassium voltage-gated channel subfamily Q member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968633', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000117013', 'approvedSymbol': 'KCNQ4', 'approvedName': 'potassium voltage-gated channel subfamily Q member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968638', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000117013', 'approvedSymbol': 'KCNQ4', 'approvedName': 'potassium voltage-gated channel subfamily Q member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968643', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000117013', 'approvedSymbol': 'KCNQ4', 'approvedName': 'potassium voltage-gated channel subfamily Q member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968648', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000117013', 'approvedSymbol': 'KCNQ4', 'approvedName': 'potassium voltage-gated channel subfamily Q member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968653', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000117013', 'approvedSymbol': 'KCNQ4', 'approvedName': 'potassium voltage-gated channel subfamily Q member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968658', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000143473', 'approvedSymbol': 'KCNH1', 'approvedName': 'potassium voltage-gated channel subfamily H member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968663', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000143473', 'approvedSymbol': 'KCNH1', 'approvedName': 'potassium voltage-gated channel subfamily H member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968668', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000143473', 'approvedSymbol': 'KCNH1', 'approvedName': 'potassium voltage-gated channel subfamily H member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968673', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000143473', 'approvedSymbol': 'KCNH1', 'approvedName': 'potassium voltage-gated channel subfamily H member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968678', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000143473', 'approvedSymbol': 'KCNH1', 'approvedName': 'potassium voltage-gated channel subfamily H member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968683', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000143473', 'approvedSymbol': 'KCNH1', 'approvedName': 'potassium voltage-gated channel subfamily H member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968688', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000182255', 'approvedSymbol': 'KCNA4', 'approvedName': 'potassium voltage-gated channel subfamily A member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968693', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000182255', 'approvedSymbol': 'KCNA4', 'approvedName': 'potassium voltage-gated channel subfamily A member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968698', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000182255', 'approvedSymbol': 'KCNA4', 'approvedName': 'potassium voltage-gated channel subfamily A member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968703', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000182255', 'approvedSymbol': 'KCNA4', 'approvedName': 'potassium voltage-gated channel subfamily A member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968708', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000182255', 'approvedSymbol': 'KCNA4', 'approvedName': 'potassium voltage-gated channel subfamily A member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968713', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000182255', 'approvedSymbol': 'KCNA4', 'approvedName': 'potassium voltage-gated channel subfamily A member 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968718', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000130037', 'approvedSymbol': 'KCNA5', 'approvedName': 'potassium voltage-gated channel subfamily A member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968723', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000130037', 'approvedSymbol': 'KCNA5', 'approvedName': 'potassium voltage-gated channel subfamily A member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968728', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000130037', 'approvedSymbol': 'KCNA5', 'approvedName': 'potassium voltage-gated channel subfamily A member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968733', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000130037', 'approvedSymbol': 'KCNA5', 'approvedName': 'potassium voltage-gated channel subfamily A member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968738', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000130037', 'approvedSymbol': 'KCNA5', 'approvedName': 'potassium voltage-gated channel subfamily A member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968743', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000130037', 'approvedSymbol': 'KCNA5', 'approvedName': 'potassium voltage-gated channel subfamily A member 5', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968748', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177272', 'approvedSymbol': 'KCNA3', 'approvedName': 'potassium voltage-gated channel subfamily A member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968753', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177272', 'approvedSymbol': 'KCNA3', 'approvedName': 'potassium voltage-gated channel subfamily A member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968758', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177272', 'approvedSymbol': 'KCNA3', 'approvedName': 'potassium voltage-gated channel subfamily A member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968763', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177272', 'approvedSymbol': 'KCNA3', 'approvedName': 'potassium voltage-gated channel subfamily A member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968768', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177272', 'approvedSymbol': 'KCNA3', 'approvedName': 'potassium voltage-gated channel subfamily A member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968773', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000177272', 'approvedSymbol': 'KCNA3', 'approvedName': 'potassium voltage-gated channel subfamily A member 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968778', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151079', 'approvedSymbol': 'KCNA6', 'approvedName': 'potassium voltage-gated channel subfamily A member 6', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968783', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151079', 'approvedSymbol': 'KCNA6', 'approvedName': 'potassium voltage-gated channel subfamily A member 6', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968788', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151079', 'approvedSymbol': 'KCNA6', 'approvedName': 'potassium voltage-gated channel subfamily A member 6', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968793', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151079', 'approvedSymbol': 'KCNA6', 'approvedName': 'potassium voltage-gated channel subfamily A member 6', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968798', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151079', 'approvedSymbol': 'KCNA6', 'approvedName': 'potassium voltage-gated channel subfamily A member 6', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968803', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151079', 'approvedSymbol': 'KCNA6', 'approvedName': 'potassium voltage-gated channel subfamily A member 6', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968808', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000129159', 'approvedSymbol': 'KCNC1', 'approvedName': 'potassium voltage-gated channel subfamily C member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968813', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000129159', 'approvedSymbol': 'KCNC1', 'approvedName': 'potassium voltage-gated channel subfamily C member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968818', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000129159', 'approvedSymbol': 'KCNC1', 'approvedName': 'potassium voltage-gated channel subfamily C member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968823', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000129159', 'approvedSymbol': 'KCNC1', 'approvedName': 'potassium voltage-gated channel subfamily C member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968828', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000129159', 'approvedSymbol': 'KCNC1', 'approvedName': 'potassium voltage-gated channel subfamily C member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968833', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000129159', 'approvedSymbol': 'KCNC1', 'approvedName': 'potassium voltage-gated channel subfamily C member 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968838', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184408', 'approvedSymbol': 'KCND2', 'approvedName': 'potassium voltage-gated channel subfamily D member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968843', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184408', 'approvedSymbol': 'KCND2', 'approvedName': 'potassium voltage-gated channel subfamily D member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968848', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184408', 'approvedSymbol': 'KCND2', 'approvedName': 'potassium voltage-gated channel subfamily D member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}, {'UUID': 'DrugTargetsIndication121923_text_968853', 'drugName': 'Amifampridine Phosphate', 'tradeNames_list': "['Firdapse']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000184408', 'approvedSymbol': 'KCND2', 'approvedName': 'potassium voltage-gated channel subfamily D member 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lambert-Eaton Myasthenic Syndrome', 'efo_term': 'Myasthenia gravis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1639 | Q16 | What Small molecule therapies have been approved by the FDA to treat somatostatinoma? | There are no drug Small molecule therapies approved to treat somatostatinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "somatostatinoma" OR LOWER(mesh_heading) = "somatostatinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1306 | Q16 | What Small molecule therapies have been approved by the FDA to treat meningioma? | There are no drug Small molecule therapies approved to treat meningioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "meningioma" OR LOWER(mesh_heading) = "meningioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1449 | Q16 | What Small molecule therapies have been approved by the FDA to treat parathyroid adenoma? | There are no drug Small molecule therapies approved to treat parathyroid adenoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "parathyroid adenoma" OR LOWER(mesh_heading) = "parathyroid adenoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.129 | Q16 | What Protein therapies have been approved by the FDA to treat chronic myeloproliferative disorder? | There are no drug Protein therapies approved to treat chronic myeloproliferative disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic myeloproliferative disorder" OR LOWER(mesh_heading) = "chronic myeloproliferative disorder") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1263 | Q16 | What Small molecule therapies have been approved by the FDA to treat lung disease? | There are no drug Small molecule therapies approved to treat lung disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lung disease" OR LOWER(mesh_heading) = "lung disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.416 | Q16 | What Small molecule therapies have been approved by the FDA to treat Duchenne muscular dystrophy? | There are no drug Small molecule therapies approved to treat Duchenne muscular dystrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "duchenne muscular dystrophy" OR LOWER(mesh_heading) = "duchenne muscular dystrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1628 | Q16 | What Small molecule therapies have been approved by the FDA to treat skin basal cell carcinoma? | There are 2 Small molecule therapy drugs that are approved to treat skin basal cell carcinoma which are as follows: Imiquimod and Vismodegib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "skin basal cell carcinoma" OR LOWER(mesh_heading) = "skin basal cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919517', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919570', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919623', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919676', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919729', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919782', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919835', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919888', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919941', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_919994', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_920047', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_920100', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_920153', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_920206', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_920259', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_920312', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072560', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072585', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072610', 'drugName': 'Vismodegib', 'tradeNames_list': "['Erivedge']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1153 | Q16 | What Small molecule therapies have been approved by the FDA to treat homozygous familial hypercholesterolemia? | There are 2 Small molecule therapy drugs that are approved to treat homozygous familial hypercholesterolemia which are as follows: Lomitapide Mesylate and Ezetimibe. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "homozygous familial hypercholesterolemia" OR LOWER(mesh_heading) = "homozygous familial hypercholesterolemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1042948', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042952', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042956', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042960', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042964', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042968', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042972', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042976', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042980', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042984', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042988', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042992', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1042996', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043000', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043004', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043008', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043012', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043016', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043020', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043024', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043028', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043032', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043036', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043040', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043044', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043048', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043052', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043056', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043060', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043064', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043068', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043072', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043076', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043080', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043084', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043088', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043092', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043096', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043100', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043104', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043108', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043112', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043116', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043120', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043124', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043128', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043132', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043136', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138823', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043140', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043144', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043148', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043152', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043156', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043160', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043164', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043168', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043172', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043176', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043180', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043184', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043188', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043192', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043196', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043200', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043204', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043208', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043212', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043216', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043220', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043224', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043228', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043232', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043236', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043240', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043244', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043248', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043252', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043256', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043260', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043264', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043268', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043272', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043276', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043280', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043284', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043288', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043292', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043296', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043300', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043304', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043308', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043312', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043316', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043320', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043324', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1043328', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185624', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097327', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097348', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097369', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1097390', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000015520', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.844 | Q16 | What Small molecule therapies have been approved by the FDA to treat brain stem neoplasm? | There are no drug Small molecule therapies approved to treat brain stem neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain stem neoplasm" OR LOWER(mesh_heading) = "brain stem neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.603 | Q16 | What Small molecule therapies have been approved by the FDA to treat Proteinuria? | There are no drug Small molecule therapies approved to treat Proteinuria. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "proteinuria" OR LOWER(mesh_heading) = "proteinuria") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.887 | Q16 | What Small molecule therapies have been approved by the FDA to treat cervical adenocarcinoma? | There are no drug Small molecule therapies approved to treat cervical adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cervical adenocarcinoma" OR LOWER(mesh_heading) = "cervical adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.952 | Q16 | What Small molecule therapies have been approved by the FDA to treat congenital adrenal hyperplasia? | Dexamethasone is the only Small molecule therapy approved by the FDA to treat congenital adrenal hyperplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "congenital adrenal hyperplasia" OR LOWER(mesh_heading) = "congenital adrenal hyperplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226384', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_226669', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_226954', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_227239', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_227524', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_227809', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_228094', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_228379', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_228664', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_228949', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_229234', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_229519', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_229804', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_230089', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_230374', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_230659', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_230944', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_231229', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_231514', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_231799', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_232084', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}, {'UUID': 'DrugTargetsIndication121923_text_232369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1670 | Q16 | What Small molecule therapies have been approved by the FDA to treat suicidal ideation? | There are no drug Small molecule therapies approved to treat suicidal ideation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "suicidal ideation" OR LOWER(mesh_heading) = "suicidal ideation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.641 | Q16 | What Small molecule therapies have been approved by the FDA to treat Stuttering? | There are no drug Small molecule therapies approved to treat Stuttering. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stuttering" OR LOWER(mesh_heading) = "stuttering") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1445 | Q16 | What Small molecule therapies have been approved by the FDA to treat papillary thyroid carcinoma? | There are 4 Small molecule therapy drugs that are approved to treat papillary thyroid carcinoma which are as follows: Vandetanib, Cabozantinib S-Malate, Sorafenib Tosylate, and Lenvatinib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "papillary thyroid carcinoma" OR LOWER(mesh_heading) = "papillary thyroid carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_209945', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_209993', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210041', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210089', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210137', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210185', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210233', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210281', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210329', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210377', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210425', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210473', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210521', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210569', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210617', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210665', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210713', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210761', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210809', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210857', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210905', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210953', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211001', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211049', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211097', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211145', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211193', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211241', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211289', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211337', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211385', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211433', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211481', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211529', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211577', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211625', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211673', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211721', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211769', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211817', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211865', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211913', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211961', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212009', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212057', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212105', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212153', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212201', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212249', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212297', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212345', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212393', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212441', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212489', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212537', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212585', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212633', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212681', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212729', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212777', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212825', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212873', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212921', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212969', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213017', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213065', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213113', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213161', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213209', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213257', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213305', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213353', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213401', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213449', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213497', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213545', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213593', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213641', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213689', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213737', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213785', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213833', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213881', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213929', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213977', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214025', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214073', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214121', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214169', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214217', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214265', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214313', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214361', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214409', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214457', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214505', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214553', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214601', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214649', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214697', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1357 | Q16 | What Small molecule therapies have been approved by the FDA to treat myositis? | There are no drug Small molecule therapies approved to treat myositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myositis" OR LOWER(mesh_heading) = "myositis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1351 | Q16 | What Small molecule therapies have been approved by the FDA to treat myeloid leukemia? | Gilteritinib Fumarate is the only Small molecule therapy approved by the FDA to treat myeloid leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myeloid leukemia" OR LOWER(mesh_heading) = "myeloid leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933930', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933932', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933934', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933936', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167601', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933938', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167601', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933940', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167601', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1072 | Q16 | What Small molecule therapies have been approved by the FDA to treat fibromyalgia? | There are 4 Small molecule therapy drugs that are approved to treat fibromyalgia which are as follows: Duloxetine Hydrochloride, Milnacipran Hydrochloride, Levomilnacipran Hydrochloride, and Pregabalin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fibromyalgia" OR LOWER(mesh_heading) = "fibromyalgia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205997', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206013', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206029', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206045', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206061', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206077', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206093', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206109', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206125', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206141', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206157', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206173', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206189', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206205', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206221', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206237', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206253', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206269', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206285', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206301', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206317', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206333', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206349', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206365', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206381', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206397', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206413', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206429', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206445', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206461', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206477', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206493', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206840', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206842', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206844', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206846', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206848', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206850', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206852', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206854', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206856', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206858', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206860', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206862', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206864', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206866', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206868', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206870', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206873', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206877', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206881', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206885', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206889', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206893', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206897', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206901', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206905', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206909', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206913', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206917', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206921', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206925', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206929', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206933', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206937', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206941', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206945', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206949', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206953', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206957', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206961', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_206965', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859327', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859379', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859431', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859483', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859535', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859587', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859639', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859691', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859743', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859795', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859847', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859899', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_859951', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860003', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860055', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860107', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860159', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860211', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860263', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860315', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860367', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860419', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860471', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860523', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860575', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860627', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860679', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}, {'UUID': 'DrugTargetsIndication121923_text_860731', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1097 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastrin-producing neuroendocrine tumor? | There are no drug Small molecule therapies approved to treat gastrin-producing neuroendocrine tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastrin-producing neuroendocrine tumor" OR LOWER(mesh_heading) = "gastrin-producing neuroendocrine tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1141 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemorrhoid? | There are 9 Small molecule therapy drugs that are approved to treat hemorrhoid which are as follows: Fluocinonide, Betamethasone Dipropionate, Dexamethasone, Hydrocortisone, Fluocinolone Acetonide, Prednisolone Acetate, Phenylephrine Hydrochloride, Lidocaine, and Nitroglycerin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemorrhoid" OR LOWER(mesh_heading) = "hemorrhoid") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220808', 'drugName': 'Fluocinonide', 'tradeNames_list': "['Fluocinonide', 'Fluocinonide emulsified base', 'Lidex', 'Lidex-e', 'MetosynMetosyn fapg', 'Vanos']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220813', 'drugName': 'Fluocinonide', 'tradeNames_list': "['Fluocinonide', 'Fluocinonide emulsified base', 'Lidex', 'Lidex-e', 'MetosynMetosyn fapg', 'Vanos']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220818', 'drugName': 'Fluocinonide', 'tradeNames_list': "['Fluocinonide', 'Fluocinonide emulsified base', 'Lidex', 'Lidex-e', 'MetosynMetosyn fapg', 'Vanos']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220836', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220848', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220860', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220872', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220884', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220896', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_220908', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_226356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_226641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_226926', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_227211', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_227496', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_227781', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_228066', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_228351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_228636', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_228921', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_229206', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_229491', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_229776', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_230061', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_230346', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_230631', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_230916', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_231201', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_231486', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_231771', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_232056', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_232341', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_240816', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_240898', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_240980', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241062', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241144', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241226', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241308', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241390', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241472', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241554', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241636', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241718', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241800', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_241882', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_242239', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_242255', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_243746', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_243763', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_243780', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_243797', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_416614', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_416632', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_416650', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_416668', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_416686', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_416704', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_637791', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_637906', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638021', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638136', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638251', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638366', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638481', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638596', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638711', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638826', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_638941', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639056', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639171', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639286', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639401', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639516', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639631', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639746', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639861', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_639976', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640091', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640206', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640321', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640436', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640551', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640666', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640781', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_640896', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641011', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641126', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641241', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641356', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641471', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641586', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641701', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641816', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_641931', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_642046', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_642161', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_642276', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_642391', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}, {'UUID': 'DrugTargetsIndication121923_text_642506', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.655 | Q16 | What Small molecule therapies have been approved by the FDA to treat Thalassemia? | There are no drug Small molecule therapies approved to treat Thalassemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thalassemia" OR LOWER(mesh_heading) = "thalassemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1338 | Q16 | What Small molecule therapies have been approved by the FDA to treat mucous membrane pemphigoid? | There are no drug Small molecule therapies approved to treat mucous membrane pemphigoid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mucous membrane pemphigoid" OR LOWER(mesh_heading) = "mucous membrane pemphigoid") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1457 | Q16 | What Small molecule therapies have been approved by the FDA to treat peptic esophagitis? | There are no drug Small molecule therapies approved to treat peptic esophagitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peptic esophagitis" OR LOWER(mesh_heading) = "peptic esophagitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.931 | Q16 | What Small molecule therapies have been approved by the FDA to treat clear cell chondrosarcoma? | There are no drug Small molecule therapies approved to treat clear cell chondrosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "clear cell chondrosarcoma" OR LOWER(mesh_heading) = "clear cell chondrosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1311 | Q16 | What Small molecule therapies have been approved by the FDA to treat mesenchymoma? | There are no drug Small molecule therapies approved to treat mesenchymoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mesenchymoma" OR LOWER(mesh_heading) = "mesenchymoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1034 | Q16 | What Small molecule therapies have been approved by the FDA to treat epilepsy with generalized tonic-clonic seizures? | There are 2 Small molecule therapy drugs that are approved to treat epilepsy with generalized tonic-clonic seizures which are as follows: Lamotrigine and Levetiracetam. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epilepsy with generalized tonic-clonic seizures" OR LOWER(mesh_heading) = "epilepsy with generalized tonic-clonic seizures") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_652999', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653030', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653061', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653092', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653123', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653154', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653185', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653216', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653247', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653278', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653309', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653340', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653371', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653402', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653433', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653464', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653495', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653526', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653557', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653588', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653619', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653650', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653681', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653712', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653743', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653774', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653805', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653836', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653867', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653898', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653929', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653960', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_653991', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654022', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654053', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654084', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654115', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654146', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654177', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654208', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654239', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654270', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654301', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654332', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654363', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654394', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654425', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654456', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654487', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654518', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654549', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654580', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654611', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654642', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654673', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654704', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654735', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654766', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654797', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654828', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654859', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654890', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654921', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654952', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_654983', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655014', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655045', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655076', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655107', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655138', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655169', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655200', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655231', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655262', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655293', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655324', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655355', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655386', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655417', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655448', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655479', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655510', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655541', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655572', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655603', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655634', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655665', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655696', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655727', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655758', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655789', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655820', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655851', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655882', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655913', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655944', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_655975', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_656006', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_656037', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}, {'UUID': 'DrugTargetsIndication121923_text_656068', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.934 | Q16 | What Small molecule therapies have been approved by the FDA to treat clostridium difficile infection? | There are no drug Small molecule therapies approved to treat clostridium difficile infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "clostridium difficile infection" OR LOWER(mesh_heading) = "clostridium difficile infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.228 | Q16 | What Protein therapies have been approved by the FDA to treat myelodysplastic/myeloproliferative disease? | There are no drug Protein therapies approved to treat myelodysplastic/myeloproliferative disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myelodysplastic/myeloproliferative disease" OR LOWER(mesh_heading) = "myelodysplastic/myeloproliferative disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.233 | Q16 | What Protein therapies have been approved by the FDA to treat neoplasm of mature B-cells? | There are no drug Protein therapies approved to treat neoplasm of mature B-cells. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neoplasm of mature b-cells" OR LOWER(mesh_heading) = "neoplasm of mature b-cells") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.717 | Q16 | What Small molecule therapies have been approved by the FDA to treat adenoma? | There are 2 Small molecule therapy drugs that are approved to treat adenoma which are as follows: Bromocriptine Mesylate and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adenoma" OR LOWER(mesh_heading) = "adenoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201338', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201345', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201352', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201359', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201366', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201373', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201380', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201387', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201394', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201401', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201408', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201415', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201422', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201429', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201436', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201443', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201450', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201457', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201464', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201471', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201478', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201485', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201492', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201499', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201506', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201513', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201520', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201527', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201534', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201541', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201548', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201555', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201562', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201569', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201576', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201583', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201590', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201597', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201604', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201611', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201618', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201625', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201632', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201639', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201646', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201653', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201660', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201667', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201674', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201681', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201688', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201695', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201702', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201709', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201716', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201723', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201730', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201737', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201744', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201751', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201758', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201765', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201772', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201779', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201786', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201793', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201800', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201807', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201814', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201821', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201828', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201835', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201842', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201849', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201856', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201863', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201870', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201877', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201884', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201891', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201898', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201905', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201912', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201919', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201926', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201933', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201940', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201947', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201954', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201961', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201968', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201975', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201982', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201989', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_201996', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_202003', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_202010', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_202017', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_202024', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}, {'UUID': 'DrugTargetsIndication121923_text_202031', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1500 | Q16 | What Small molecule therapies have been approved by the FDA to treat portal hypertension? | There are no drug Small molecule therapies approved to treat portal hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "portal hypertension" OR LOWER(mesh_heading) = "portal hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1575 | Q16 | What Small molecule therapies have been approved by the FDA to treat respiratory failure? | Nitric Oxide is the only Small molecule therapy approved by the FDA to treat respiratory failure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory failure" OR LOWER(mesh_heading) = "respiratory failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974154', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974208', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974262', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974316', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974370', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974424', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974478', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974532', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974586', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974640', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974694', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974748', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974802', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974856', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974910', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974964', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975018', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975072', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975126', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975180', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975234', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975288', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975342', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975396', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975450', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975504', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975558', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975612', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975666', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975720', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975774', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975828', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975882', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975936', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975990', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976044', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976098', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976152', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976206', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976260', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976314', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976368', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976422', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976476', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976530', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976584', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976638', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976692', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976746', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976800', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976854', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976908', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976962', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977016', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977070', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977124', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977178', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977232', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977286', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977340', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977394', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977448', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977502', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977556', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977610', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977664', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977718', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977772', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977826', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977880', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977934', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_977988', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978042', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978096', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978150', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978204', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978258', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978312', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978366', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978420', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978474', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978528', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978582', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978636', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978690', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978744', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978798', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978852', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978906', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_978960', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979014', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979068', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979122', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979176', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979230', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979284', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979338', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979392', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979446', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_979500', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.164 | Q16 | What Protein therapies have been approved by the FDA to treat graft versus host disease? | There are no drug Protein therapies approved to treat graft versus host disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "graft versus host disease" OR LOWER(mesh_heading) = "graft versus host disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.654 | Q16 | What Small molecule therapies have been approved by the FDA to treat Tetralogy of Fallot? | There are no drug Small molecule therapies approved to treat Tetralogy of Fallot. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tetralogy of fallot" OR LOWER(mesh_heading) = "tetralogy of fallot") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1129 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemangioendothelioma? | There are no drug Small molecule therapies approved to treat hemangioendothelioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemangioendothelioma" OR LOWER(mesh_heading) = "hemangioendothelioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.268 | Q16 | What Protein therapies have been approved by the FDA to treat prediabetes syndrome? | There are no drug Protein therapies approved to treat prediabetes syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prediabetes syndrome" OR LOWER(mesh_heading) = "prediabetes syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.149 | Q16 | What Protein therapies have been approved by the FDA to treat dry eye syndrome? | There are no drug Protein therapies approved to treat dry eye syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dry eye syndrome" OR LOWER(mesh_heading) = "dry eye syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.956 | Q16 | What Small molecule therapies have been approved by the FDA to treat constipation disorder? | There are 4 Small molecule therapy drugs that are approved to treat constipation disorder which are as follows: Naloxegol Oxalate, Naldemedine Tosylate, Tenapanor Hydrochloride, and Lubiprostone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "constipation disorder" OR LOWER(mesh_heading) = "constipation disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763351', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763353', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763355', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763357', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763359', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763361', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763363', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763365', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763367', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763369', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763371', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763373', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763376', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763379', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763382', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763385', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094305', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094309', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094313', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094317', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193387', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193392', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193397', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193402', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193407', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193412', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193417', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193422', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193427', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193432', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193437', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193442', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193447', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193452', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193457', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193462', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193467', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193472', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1021 | Q16 | What Small molecule therapies have been approved by the FDA to treat endometrial neoplasm? | There are no drug Small molecule therapies approved to treat endometrial neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "endometrial neoplasm" OR LOWER(mesh_heading) = "endometrial neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.580 | Q16 | What Small molecule therapies have been approved by the FDA to treat POEMS syndrome? | There are no drug Small molecule therapies approved to treat POEMS syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "poems syndrome" OR LOWER(mesh_heading) = "poems syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.772 | Q16 | What Small molecule therapies have been approved by the FDA to treat anterior ischemic optic neuropathy? | There are no drug Small molecule therapies approved to treat anterior ischemic optic neuropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anterior ischemic optic neuropathy" OR LOWER(mesh_heading) = "anterior ischemic optic neuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1388 | Q16 | What Small molecule therapies have been approved by the FDA to treat non-alcoholic fatty liver disease? | There are no drug Small molecule therapies approved to treat non-alcoholic fatty liver disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "non-alcoholic fatty liver disease" OR LOWER(mesh_heading) = "non-alcoholic fatty liver disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.308 | Q16 | What Protein therapies have been approved by the FDA to treat thymus neoplasm? | There are no drug Protein therapies approved to treat thymus neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thymus neoplasm" OR LOWER(mesh_heading) = "thymus neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.193 | Q16 | What Protein therapies have been approved by the FDA to treat juvenile dermatomyositis? | There are no drug Protein therapies approved to treat juvenile dermatomyositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "juvenile dermatomyositis" OR LOWER(mesh_heading) = "juvenile dermatomyositis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.647 | Q16 | What Small molecule therapies have been approved by the FDA to treat T-lymphoblastic lymphoma? | There are no drug Small molecule therapies approved to treat T-lymphoblastic lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "t-lymphoblastic lymphoma" OR LOWER(mesh_heading) = "t-lymphoblastic lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.311 | Q16 | What Protein therapies have been approved by the FDA to treat type 1 diabetes mellitus? | There are no drug Protein therapies approved to treat type 1 diabetes mellitus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "type 1 diabetes mellitus" OR LOWER(mesh_heading) = "type 1 diabetes mellitus") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1160 | Q16 | What Small molecule therapies have been approved by the FDA to treat hyperlipoproteinemia? | There are no drug Small molecule therapies approved to treat hyperlipoproteinemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperlipoproteinemia" OR LOWER(mesh_heading) = "hyperlipoproteinemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.64 | Q16 | What Protein therapies have been approved by the FDA to treat Sezary's disease? | There are no drug Protein therapies approved to treat Sezary's disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sezary's disease" OR LOWER(mesh_heading) = "sezary's disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.925 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic rhinosinusitis? | There are no drug Small molecule therapies approved to treat chronic rhinosinusitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic rhinosinusitis" OR LOWER(mesh_heading) = "chronic rhinosinusitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1754 | Q16 | What Small molecule therapies have been approved by the FDA to treat viral disease? | There are 3 Small molecule therapy drugs that are approved to treat viral disease which are as follows: Imiquimod, Ribavirin, and Maraviroc. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "viral disease" OR LOWER(mesh_heading) = "viral disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919513', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919566', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919619', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919672', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919725', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919778', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919831', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919884', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919937', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_919990', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_920043', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_920096', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_920149', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_920202', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_920255', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_920308', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_937563', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_937588', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938285', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938306', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938327', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938348', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938369', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938390', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938411', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938432', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938453', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938474', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938495', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938516', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938537', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938558', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}, {'UUID': 'DrugTargetsIndication121923_text_938579', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1125 | Q16 | What Small molecule therapies have been approved by the FDA to treat head and neck squamous cell carcinoma? | There are no drug Small molecule therapies approved to treat head and neck squamous cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "head and neck squamous cell carcinoma" OR LOWER(mesh_heading) = "head and neck squamous cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1658 | Q16 | What Small molecule therapies have been approved by the FDA to treat status epilepticus? | There are 2 Small molecule therapy drugs that are approved to treat status epilepticus which are as follows: Midazolam and Lorazepam. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "status epilepticus" OR LOWER(mesh_heading) = "status epilepticus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_948540', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_948643', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_948746', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_948849', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_948952', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949055', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949158', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949261', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949364', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949467', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949570', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949673', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949776', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949879', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_949982', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950085', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950188', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950291', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950394', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950497', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950600', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950703', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950806', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_950909', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951012', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951115', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951218', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951321', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951424', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951527', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951630', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951733', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951836', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_951939', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952042', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952145', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952248', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952351', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952454', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952557', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952660', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952763', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952866', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_952969', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953072', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953175', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953278', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953381', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953484', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953587', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953690', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953793', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953896', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_953999', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954102', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954205', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954308', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954411', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954514', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954617', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954720', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954823', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_954926', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955029', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955132', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955235', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955338', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955441', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955544', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955647', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955750', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955853', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_955956', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956059', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956162', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956265', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956368', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956471', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956574', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956677', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956780', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956883', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_956986', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957089', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957192', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957295', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957398', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957501', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957604', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957707', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957810', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_957913', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958016', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958119', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958222', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958325', 'drugName': 'Midazolam', 'tradeNames_list': "['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chlorideNayzilam']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958470', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958497', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958524', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}, {'UUID': 'DrugTargetsIndication121923_text_958551', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Status Epilepticus', 'efo_term': 'status epilepticus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1342 | Q16 | What Small molecule therapies have been approved by the FDA to treat muscle atrophy? | There are no drug Small molecule therapies approved to treat muscle atrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "muscle atrophy" OR LOWER(mesh_heading) = "muscle atrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.786 | Q16 | What Small molecule therapies have been approved by the FDA to treat appendix carcinoma? | There are no drug Small molecule therapies approved to treat appendix carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "appendix carcinoma" OR LOWER(mesh_heading) = "appendix carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.852 | Q16 | What Small molecule therapies have been approved by the FDA to treat bronchogenic carcinoma? | There are no drug Small molecule therapies approved to treat bronchogenic carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchogenic carcinoma" OR LOWER(mesh_heading) = "bronchogenic carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.625 | Q16 | What Small molecule therapies have been approved by the FDA to treat Sjogren syndrome? | There are no drug Small molecule therapies approved to treat Sjogren syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sjogren syndrome" OR LOWER(mesh_heading) = "sjogren syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1546 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulmonary arterial hypertension? | There are 8 Small molecule therapy drugs that are approved to treat pulmonary arterial hypertension which are as follows: Treprostinil, Epoprostenol Sodium, Selexipag, Riociguat, Nitric Oxide, Ambrisentan, Bosentan, and Tadalafil. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary arterial hypertension" OR LOWER(mesh_heading) = "pulmonary arterial hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244449', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244450', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244466', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244467', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244483', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244484', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244500', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244501', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244517', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244518', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244534', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244535', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244551', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244552', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244568', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244569', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244585', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244586', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244602', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244603', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244619', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244620', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244636', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244637', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244653', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244654', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244670', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244671', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244687', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244688', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244704', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244705', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244721', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244722', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244738', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244739', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244755', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244756', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244772', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244773', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244789', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244790', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244806', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244807', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244823', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244824', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244840', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244841', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244857', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244858', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244874', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244875', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244891', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244892', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244908', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244909', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244925', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244926', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244942', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244943', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244959', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244960', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244976', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244977', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244993', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_244994', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245010', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245011', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245027', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245028', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245044', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245045', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245061', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245062', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245078', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245079', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245095', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245096', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245112', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245113', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245129', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245130', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245146', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245147', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245163', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245164', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245180', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245181', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245197', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245198', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245214', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245215', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245231', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245232', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245248', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245249', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245265', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245266', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245282', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_245283', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1217 | Q16 | What Small molecule therapies have been approved by the FDA to treat intraepithelial neoplasia? | There are no drug Small molecule therapies approved to treat intraepithelial neoplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intraepithelial neoplasia" OR LOWER(mesh_heading) = "intraepithelial neoplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1622 | Q16 | What Small molecule therapies have been approved by the FDA to treat shortness of breath? | There are no drug Small molecule therapies approved to treat shortness of breath. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "shortness of breath" OR LOWER(mesh_heading) = "shortness of breath") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1265 | Q16 | What Small molecule therapies have been approved by the FDA to treat lupus nephritis? | There are no drug Small molecule therapies approved to treat lupus nephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lupus nephritis" OR LOWER(mesh_heading) = "lupus nephritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.220 | Q16 | What Protein therapies have been approved by the FDA to treat metastasis? | Octreotide Acetate is the only Protein therapy approved by the FDA to treat metastasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "metastasis" OR LOWER(mesh_heading) = "metastasis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1042019', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042040', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042061', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042082', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042103', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042124', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042145', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042166', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042187', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000162009', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042208', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042229', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042250', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042271', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042292', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042313', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042334', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042355', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042376', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000180616', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042397', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042418', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042439', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042460', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042481', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042502', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042523', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042544', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042565', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000278195', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042586', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042607', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042628', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042649', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042670', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042691', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042712', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042733', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042754', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000139874', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042775', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042796', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042817', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042838', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042859', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042880', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042901', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042922', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1042943', 'drugName': 'Octreotide Acetate', 'tradeNames_list': "['Bynfezia pen', 'Mycapssa', 'Octreotide acetateOctreotide acetate (preservative free)Octreotide acetate preservative free', 'Sandostatin', 'Sandostatin lar']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000132671', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1155 | Q16 | What Small molecule therapies have been approved by the FDA to treat humerus fracture? | There are no drug Small molecule therapies approved to treat humerus fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "humerus fracture" OR LOWER(mesh_heading) = "humerus fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.288 | Q16 | What Protein therapies have been approved by the FDA to treat secondary hyperparathyroidism? | Velcalcetide is the only Protein therapy approved by the FDA to treat secondary hyperparathyroidism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "secondary hyperparathyroidism" OR LOWER(mesh_heading) = "secondary hyperparathyroidism") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148947', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148950', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148953', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148956', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148959', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148962', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148965', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148968', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148971', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148974', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148977', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148980', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148983', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148986', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148989', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148992', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148995', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1148998', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1149001', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1149004', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_1149007', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1506 | Q16 | What Small molecule therapies have been approved by the FDA to treat postherpetic neuralgia? | There are 2 Small molecule therapy drugs that are approved to treat postherpetic neuralgia which are as follows: Lidocaine and Gabapentin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "postherpetic neuralgia" OR LOWER(mesh_heading) = "postherpetic neuralgia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637797', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_637912', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638027', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638142', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638257', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638372', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638487', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638602', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638717', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638832', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_638947', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639062', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639177', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639292', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639407', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639522', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639637', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639752', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639867', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_639982', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640097', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640212', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640327', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640442', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640557', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640672', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640787', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_640902', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641017', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641132', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641247', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641362', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641477', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641592', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641707', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641822', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_641937', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642052', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642167', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642282', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642397', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642512', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642627', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642742', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642857', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_642972', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643087', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643202', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643317', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643432', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643547', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643662', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_643892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_644007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_644122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_644237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_644352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_644467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_644582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_894743', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_894807', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_894871', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_894935', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_894999', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895063', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895127', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895191', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895255', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895319', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895383', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895447', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895511', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895575', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895639', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895703', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895767', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895831', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895895', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_895959', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896023', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896087', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896151', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896215', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896279', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896343', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896407', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896471', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896535', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896599', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896663', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896727', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896791', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896855', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896919', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_896983', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_897047', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_897111', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_897175', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}, {'UUID': 'DrugTargetsIndication121923_text_897239', 'drugName': 'Gabapentin', 'tradeNames_list': "['Gabapentin', 'Gralise', 'Neurontin']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1415 | Q16 | What Small molecule therapies have been approved by the FDA to treat orthostatic hypotension? | There are no drug Small molecule therapies approved to treat orthostatic hypotension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "orthostatic hypotension" OR LOWER(mesh_heading) = "orthostatic hypotension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.